lead to premature death. '6 What should the doctor do when dealing with a patient with an occupational disease who has just died? The safest course is to report the death to the coroner or procurator fiscal, who will in most cases decide that a necropsy is necessary. For a general practitioner, this is often the only practicable step to take. If there is serious doubt whether the occupational disease contributed to death it is reasonable simply to obtain a necropsy and let the pathologist decide whether the death should be reported. This most frequently occurs when the patient is known to have been exposed to asbestos, does not have clinical evidence of asbestosis, and has died of lung cancer. A necropsy should always be requested in such patients as the likelihood that the asbestos exposure contributed to the cancer is increased if there is pathological evidence of asbestosis7; this evidence may be of considerable value in any subsequent litigation. More importantly, necropsy evidence allows the doctor to give an impartial and more confident explanation of the cause of death to bereaved relatives, allowing them to come more easily to terms with their loss and to make rational decisions about possible litigation.
Finally, it should be remembered that necropsy is not infallible.8 Patchy fibrosis is commonly present in the lungs of smokers, and distinguishing this from early asbestosis may be difficult. In such cases the expensive and time consuming procedure of quantification and identification of asbestos fibres in the lungs may be required. 9 The necessary skill and equipment take it outside the reach of clinical pathology departments, and the results may still be equivocal; it is usually performed only for research or at the request and expense of lawyers and their clients. Will the new antipsychotics improve the treatment of schizophrenia?
Depot preparations still hold the key to compliance Non-compliance with neuroleptic treatment is an obstacle to the success of community care for patients with mental illness. It occurs in 8-16% of inpatients but in 33-54% of outpatients taking drugs by mouth. 12 The rates are much lower with depot administration,' and this accounts for its continued popularity. Non-compliant patients consume more resources; they are more severely ill at the point of admission than those who are readmitted despite compliance, they are more likely to be admitted compulsorily, they have longer inpatient stays, and they have a higher long term readmission rate.4 So how else (apart from depot treatment) might compliance be improved? Attention to minimising extrapyramidal side effects is said to be important,5 although one study showed that non-compliance with treatment was even higher for antiparkinsonian drugs than for neuroleptics. Many other factors are known to relate to non-compliance with neuroleptic treatment: these include lack of insight,6 (which does not necessarily return after clinical recovery and may be interpreted as denial of illness and resistance to treatment7) and the occurrence of dysphoria or depression.8 One study showed a strong inverse relation between compliance and depression but not with the presence of extrapyramidal side effects.9 Other factors include galactorrhoea,"°coexistent alcohol abuse," poor or unstable housing,'2 and a poor relation between patient and service providers."
Compliance may be improved by creative approaches such as linking a free lunch to an injection at a morning depot clinic BMJ VOLUME 307 attended by hungry patients.14 At present, however, depot neuroleptics (even though they are no more effective than oral forms 15) remain the best authenticated method of preventing relapse in non-compliant, forgetful or treatment-resistant patients."l Will this picture change now that many new antipsychotics (generally referred to as atypical, although all this means is that they lack extrapyramidal side effects, which not all do) are becoming available? The atypical neuroleptics fall roughly into five groups: the later substituted benzamides; the mixed dopamine and serotonin receptor antagonists; the dopamine specific compounds; serotonin receptor antagonists; and sigma receptor antagonists. These new drugs differ from those in current use not only in their actions but also in their method of delivery. At present five of the six neuroleptics most used in Britain are available in depot form. About half the neuroleptics used in patients with schizophrenia are depot formulations. 17 By contrast, few of the new drugs in development will initially be available as depot preparations. The dopamine receptor antagonist raclopride is being developed in depot form, as is the serotonin receptor antagonist sertindole, but generally the manufacturers have shown little enthusiasm for the extra work required to develop depot preparations. This is understandable for clozapine-no one would be keen to give a depot form of a drug known to carry a risk of causing agranulocytosis. No such risk is apparent from existing data on remoxipride, launched in 1991, and risperidone, launched in 1993. Attaching decanoate or ethanoate side chains to the atypical neuroleptics is not proving easy, but this is not the main reason for the lack of depot versions. Depot preparations are believed to be unnecessary-because they are thought to be needed only for drugs with unacceptable side effects.
The true atypical neuroleptics will, by definition, lack extrapyramidal side effects, but do the data support the comfortable assumption that non-compliance is caused principally by side effects? This has scarcely been proved for comparisons of serotonin reuptake inhibitors with tricyclic antidepressants,'8 and the research reviewed earlier in this article has shown the multiple factors relevant to noncompliance with neuroleptic treatment. Might it not be premature to abandon our tried and trusted reliance on depot administration to overcome non-compliance in patients with schizophrenia?
At this stage it seems remarkably naive to assume that patients with chronic schizophrenia will readily swallow the neuroleptics in oral form. Quite possibly the negative symptoms of schizophrenia also influence compliance rates (largely unstudied) perhaps by being confounded with insight.
Insight itself, drug related depression, and other specific and non-specific psychological factors all play their parts in determining compliance. It would be unfortunate if marketing models built on naive assumptions delayed the introduction of new drugs likely to have a major impact on response to treatment. The delivery system most likely to offer the long term benefits of new drugs to patients with recalcitrant chronic schizophrenia is the well tried depot system. Since 1979 the NHS has been transformed into a series of quangos directed mostly by businessmen with Conservative leanings, usually selected more for their professional position than for their identification with the local community.' No body of administrative law has been developed to regulate their activities.2 Equipped with a mission statement of effectiveness and efficiency they have been freed from the constraints of formal accountability to those who use the NHS and pay for it through taxes.3
Despite their lack of accountability to the public they serve, NHS managers are currently being exhorted by their political masters to listen to "local voices." Undoubtedly, the exhortations have spawned a lucrative industry in "communication strategies," the net cost of which has not been estimated. While health authorities and trusts pilot expensive public consultation exercises, sometimes in conjunction with other quangos, there is little evidence of any firm commitment to allow the public to influence purchasing decisions.4 The reason for this is obvious: quangos have no reason to be concerned with what the public think about them. In Local Voices the NHS Management Executive tries to provide them with the necessary motivation. It says that involving local people in the purchasing process will enhance the credibility of health authorities, provide them with greater
